Combination Therapies in IBD: Assessing the Evidence for and Against

Content Type: presentation

Presenter: Speaker: Stephen B. Hanauer, MD, FACG; Moderator: Mark C. Mattar, MD, FACG

Presenter Disclosure: Stephen B. Hanauer, MD, FACG : Abbvie Consultant, Clinical Research (Institution), Speaker ; Allergan Consultant, Clinical Research (Institution) ;Amgen Consultant, Clinical Research (Institution); Arena Consultant, DSMB; Boehringer-Ingelheim Consultant, DSMB; BMS Consultant, DSMB; Celgene Consultant, Clinical Research (Institution); Celttrion Consultant; Genentech Consultant, Clinical Research, (Institution); Gilead Consultant, Clinical Research (Institution); GSK Consultant, Clinical Research (Institution); Janssen Consultant, Clinical Research (Institution), Speaker; Lilly Consultant, Clinical Research (Institution); Merck Consultant; Novartis Consultant, Clinical Research (Institution); Pfizer Consultant, Clinical Research (Institution), Speaker; Progenity Consultant; Prometheus Consultant, Clinical Research (Institution); Protagonist Consultant, DSMB; Receptos Conslutant, Clinical Research (Institution), Salix (Consultant); Samsung Bioepis Consultant; Seres Therapeutics Consultant, Clinical Research (Institution); Takeda Consultant, Clinical Research (Institution), Speaker; UCB Consultant, Clinical Research (Institution), VHsquared Consultant ; Mark C. Mattar, MD, FACG : AbbVie: Consultant, Speakers Bureau; Janssen: Consultant, Speakers Bureau; Takeda: Consultant, Speakers Bureau; Pfizer: Consultant, Speakers Bureau

Event: ACG Virtual Grand Rounds

Release Date: 9/11/2020

Expiration Date: 9/11/2023

Objective: Discuss evidence for combining therapies to improve efficacy in UC and CD, review risks of combining therapies in UC and CD, and consider when to stop combination therapy in UC and CD.